PL
PLRX.US Pliant Therapeutics Inc
- Market cap
- USD 43.0M
- P/E
- -
- P/B
- 0.34x
- ROE
- -70.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PLRX.US undervalued?
Graham numberThe Graham number of Pliant Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pliant Therapeutics Inc fundamental analysis
No fundamental analysis for Pliant Therapeutics Inc yet.
Pliant Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusin…
Full company profilePliant Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pliant Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 0.00 | 57.1M | 41.8M | 7.57M | 9.69M | 1.58M | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | -666K | 57.1M | 41.8M | 7.57M | 9.69M | 1.58M | -2.13M | -1.70M | - |
| Operating Income | -18.3M | -30.9M | -1.23M | -41.6M | -20.0M | -127M | -184M | -228M | -150M | -95.2M |
| EBITDA | -18.1M | -30.2M | -118K | -40.3M | -18.5M | -121M | -158M | -205M | -145M | -88.1M |
| Net Income | -20.6M | -30.3M | -631K | -39.7M | -17.9M | -123M | -161M | -210M | -149M | -89.1M |
| EPS | -26 | -1.83 | -0.02 | -1.12 | -0.50 | -2.94 | -2.75 | -3.47 | -2.43 | -1.44 |
| Balance Sheet | ||||||||||
| Total Assets | 6.55M | 66.5M | 119M | 296M | 221M | 351M | 512M | 397M | 225M | 170M |
| Total Liabilities | 3.19M | 67.4M | 119M | 12.5M | 22.2M | 37.3M | 38.6M | 92.9M | 44.0M | 43.2M |
| Shareholders' Equity | 3.35M | -882K | -435K | 283M | 199M | 313M | 474M | 304M | 181M | 127M |
| Cash & Short-term Investments | 4.25M | 60.9M | 103M | 277M | 201M | 331M | 494M | 356M | 191M | 141M |
| Total Debt | - | 525K | 444K | 283K | 7.19M | 15.8M | 11.4M | 60.2M | 29.1M | 27.8M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -16.9M | -28.3M | -2.75M | -37.3M | -75.4M | -94.6M | -116M | -156M | -128M | -65.3M |
| Capital Expenditure | 1.41M | 2.32M | 964K | 1.53M | 1.95M | 1.76M | 921K | 3.85M | 374K | 0.00 |
| Free Cash Flow | -18.3M | -30.7M | -3.71M | -38.8M | -77.4M | -96.4M | -117M | -159M | -129M | -65.3M |
| Ratios | ||||||||||
| ROE | -616.5% | - | - | -14.0% | -9.0% | -39.4% | -34.1% | -69.2% | -82.4% | -70.3% |
| ROA | -314.7% | -45.5% | -0.5% | -13.4% | -8.1% | -35.2% | -31.5% | -53.0% | -66.3% | -52.4% |
| Net Profit Margin | - | - | -1.1% | -95.0% | -236.5% | -1,273.3% | -10,211.1% | - | - | - |
| Debt to Equity | - | - | - | 0.00x | 0.04x | 0.05x | 0.02x | 0.20x | 0.16x | 0.22x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pliant Therapeutics Inc dividends
Pliant Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Who owns Pliant Therapeutics Inc
- Insiders 2.23%
- Institutions 76.68%
- Public & others 21.10%
- Shares outstanding 62.0M
- Free float 55.0M
Top funds holding PLRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.75M | 2.82% | 0.00% | Sep 2026 |
| Bridgeway Ultra-Small Company | 471K | 0.76% | 0.00% | Jun 2026 |
| Sun Life Global Mid Cap Fund I | 374K | 0.60% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 349K | 0.56% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 188K | 0.30% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 156K | 0.25% | +0.11% | Sep 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 96.1K | 0.16% | +519.98% | Jun 2026 |
| Fidelity Total Market Index | 94.8K | 0.15% | 0.00% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 80.0K | 0.13% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 79.9K | 0.13% | 0.00% | Sep 2026 |
| Multi-Manager Small Cap Eq Strat Inst | 52.6K | 0.08% | 0.00% | Sep 2026 |
| NVIT Small Cap Val I | 50.3K | 0.08% | 0.00% | Jun 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 46.2K | 0.07% | 0.00% | Sep 2026 |
| GS Absolute Ret Trkr I Acc EUR Hdg | 37.6K | 0.06% | 0.00% | Aug 2026 |
| Fidelity Nasdaq Composite Index | 23.3K | 0.04% | 0.00% | Aug 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 21.7K | 0.04% | 0.00% | Oct 2026 |
| Vanguard U.S. Eq Idx £ Acc | 19.5K | 0.03% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 13.8K | 0.02% | 0.00% | Sep 2026 |
| JNL/DFA US Small Cap A | 9.54K | 0.02% | 0.00% | Sep 2026 |
| AST Small-Cap Equity Portfolio | 7.40K | 0.01% | 0.00% | Sep 2026 |
Top institutions holding PLRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 6.14M | 9.91% | -0.03% | Jun 2026 |
| ADAR1 Capital Management LLC | 5.51M | 8.89% | +113.13% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.44M | 3.94% | +4.15% | Jun 2026 |
| Acadian Asset Management LLC | 2.42M | 3.90% | 0.00% | Sep 2026 |
| Two Sigma Investments LLC | 2.26M | 3.65% | +0.43% | Jun 2026 |
| Citadel Advisors Llc | 2.14M | 3.46% | -33.61% | Jun 2026 |
| Renaissance Technologies Corp | 2.05M | 3.31% | +0.22% | Sep 2026 |
| Monaco Asset Management | 1.94M | 3.13% | 0.00% | Jun 2026 |
| Lynx1 Capital Management, LP | 1.80M | 2.90% | 0.00% | Jun 2026 |
| BML Capital Management LLC | 1.55M | 2.49% | 0.00% | Sep 2026 |
| Prosight Management, LP | 1.37M | 2.21% | -17.83% | Jun 2026 |
| Peapod Lane Capital LLC | 1.31M | 2.11% | +1.59% | Jun 2026 |
| Woodline Partners LP | 1.30M | 2.09% | -22.22% | Jun 2026 |
| BlackRock Inc | 1.15M | 1.86% | +5.00% | Jun 2026 |
| Ikarian Capital, LLC | 1.00M | 1.61% | 0.00% | Jun 2026 |
| Eversept Partners, LP | 891K | 1.44% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 835K | 1.35% | -16.15% | Jun 2026 |
| Redmile Group, LLC | 772K | 1.25% | 0.00% | Jun 2026 |
| JPMorgan Chase & Co | 682K | 1.10% | -20.91% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 643K | 1.04% | -10.50% | Jun 2026 |
Pliant Therapeutics Inc company profile
- Company name
- Pliant Therapeutics Inc
- Ticker
- PLRX.US
- Exchange
- USA Stocks
- Listed since
- Jun 3, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 49
- Fiscal year end
- December
- Address
- 331 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
- Phone
- 650 481 6770
- Website
- pliantrx.com
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Pliant Therapeutics Inc management
10- Dr. Bernard Jozef Coulie M.B.A., M.D., Ph.D.President, CEO & Director · born 1966
- Dr. Keith Lamont Cummings M.B.A., M.D.Chief Financial Officer · born 1977
- Ms. Minnie KuoChief Operating Officer · born 1981
- Dr. Rik Derynck Ph.D.Scientific Founder & Member of Scientific Advisory Board
- Mr. Dean Sheppard M.D.Scientific Founder & Member of Scientific Advisory Board
- Mr. Bill DeGrado Ph.D.Scientific Founder
- Mr. Hal Chapman M.D.Scientific Founder & Member of Scientific Advisory Board
- Ms. Delphine Imbert Ph.D.Chief Technical Officer
- Mr. Christopher S. KeenanVice President of Investor Relations & Corporate Communications
- Ms. Lily CheungChief Human Resources Officer · born 1973